Cagrilintide
Also known as: AM833, NN9838, Long-acting amylin analog
Cagrilintide (also called AM833 or NN9838) is an investigational amylin analog. Cagrilintide is a long-acting analog of human amylin, the beta-cell hormone co-secreted with insulin. Substitutions that reduce the aggregation seen with native human amylin, together with fatty-acid acylation that promotes albumin binding, extend its half-life enough for weekly dosing.
For research use only.
Key Facts
- CAS
- 1415456-99-3
- Molecular Weight (MW)
- ~4749 g/mol
- Half-life
- ~6–7 days
- FDA status
- Investigational New Drug (IND)
- Evidence level
- Clinical Trial Evidence
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Once weekly
- Last updated
- Sep 26, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Amylin receptorCalcitonin receptor
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Oct 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 36
- Listed offers
- 81
- Median price per mg
- $12.00/mg
- Typical $8.80–$16.25/mg
Research summary
Long-acting amylin analog from Novo Nordisk in Phase 3 obesity programs, including the CagriSema combination with semaglutide. Not FDA-approved as of 2026.
Peptide Library's Cagrilintide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Cagrilintide dosage chart
Cagrilintide has no approved dosage. Human dosing comes from Novo Nordisk's registered programme, where 2.4 mg subcutaneously once weekly is the dose carried through phase 3, almost always co-administered with semaglutide 2.4 mg as the fixed combination CagriSema. Most published efficacy is for that combination rather than for cagrilintide alone.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.3–4.5 mg once weekly studied; 2.4 mg once weekly carried into phase 3 |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | Up to 68 weeks in the phase 3 programme |
| Titration | Stepwise weekly escalation inside the trial protocol, reaching 2.4 mg. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| REDEFINE 1 — phase 3, coadministered with semaglutideClinical trial · Phase 3 randomised controlled trial | Adults with overweight or obesity | Cagrilintide 2.4 mg with semaglutide 2.4 mg (CagriSema) | Subcutaneous | Once weekly | 68 weeks | Percentage change in body weight | Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. |
| REIMAGINE 2 — phase 3, versus semaglutide or cagrilintide aloneClinical trial · Phase 3 double-blind randomised controlled trial | People with type 2 diabetes | Cagrilintide 2.4 mg, alone and combined with semaglutide 2.4 mg | Subcutaneous | Once weekly | Per trial protocol | Glycaemic control and body weight | Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026. |
| NCT04982575 — phase 2, results postedClinical trial · Phase 2 trial with posted results | Adults with overweight or obesity (n=92) | Per trial protocol | Subcutaneous | Once weekly | Per trial protocol | Cagrilintide with semaglutide, safety and efficacy | NCT04982575 — Research Study to Look at How Well Cagrilintide Together With Semaglutide Works |
| NCT05669755 — REDEFINE 3, phase 3 cardiovascular outcomesClinical trial · Phase 3 outcomes trial, active not recruiting | Adults with overweight or obesity and cardiovascular disease (n=7101) | Per trial protocol (CagriSema) | Subcutaneous | Once weekly | Per trial protocol | Cardiovascular outcomes | NCT05669755 — REDEFINE 3: A Research Study to See the Effects of CagriSema |
Where sources disagree
- Most phase 3 efficacy attributed to cagrilintide comes from CagriSema, a fixed combination with semaglutide. Weight loss reported for the combination cannot be attributed to cagrilintide alone, and the REIMAGINE 2 design is one of the few that separates them.
- Cagrilintide is not approved by any regulator. Dosing quoted for it is trial dosing, administered under monitoring with protocol-driven escalation.
- Cagrilintide is an amylin analogue, a different mechanism from the GLP-1 and GIP agonists it is usually grouped with. Dosing intuition carried over from semaglutide or tirzepatide does not transfer to it.
Reconstitution
Common research vial sizes: 5 mg, 10 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- 2 mL BAC water for 5 mg vial
- Injection Sites
- AbdomenThigh
- Concentration Example
- 5 mg / 2 mL = 2.5 mg/mL
- Timing Notes
- Morning; same day weekly
- Expected Onset
- 1-2 weeks appetite, 4-8 weeks weight loss
How to reconstitute Cagrilintide
- Check the vial size and diluent volume. The profile example for Cagrilintide is: 2 mL BAC water for 5 mg vial.
- Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
- Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
- Record the resulting concentration: 5 mg / 2 mL = 2.5 mg/mL.
- Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a dose in mcg into syringe units.
Sequence & molecular data
| Amino acid sequence | Modified amylin peptide, engineered for long-acting stability |
|---|---|
| Molecular formula | Not publicly available |
| Molecular weight | ~4749 g/mol |
| CAS number | 1415456-99-3 |
| Half-life | ~6–7 days |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 171397054 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Cagrilintide is a long-acting analog of human amylin, the beta-cell hormone co-secreted with insulin. Substitutions that reduce the aggregation seen with native human amylin, together with fatty-acid acylation that promotes albumin binding, extend its half-life enough for weekly dosing. It is a dual agonist at amylin and calcitonin receptors, acting on the area postrema and other hindbrain nuclei to slow gastric emptying, suppress post-prandial glucagon, and reduce food intake. Because that satiety pathway is separate from the GLP-1 pathway, the two are being developed together — the rationale behind the cagrilintide-semaglutide combination.
Origin
Synthetic long-acting human amylin analog.
Targets
Studies
- Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Regulatory & research status
Cagrilintide has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
Benefits
Cagrilintide side effects
The effects below are those reported in Cagrilintide clinical trials; long-term safety data may still be limited.
Side Effects
- Nausea
- Constipation
- Injection-site reactions
- GI effects when combined with GLP-1s
Contraindications
- Medullary thyroid carcinoma
- Severe GI disease
Stacking
Common stacking partners
Combinations that include Cagrilintide, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Cagrilintide: frequently asked questions
What is Cagrilintide?
Long-acting amylin analog from Novo Nordisk in Phase 3 obesity programs, including the CagriSema combination with semaglutide. Not FDA-approved as of 2026. Cagrilintide is a long-acting analog of human amylin, the beta-cell hormone co-secreted with insulin. Substitutions that reduce the aggregation seen with native human amylin, together with fatty-acid acylation that promotes albumin binding, extend its half-life enough for weekly dosing.
What are the side effects of Cagrilintide?
Side effects recorded for Cagrilintide from clinical-trial reports include nausea, constipation, injection-site reactions and GI effects when combined with GLP-1s. Cautions recorded on this profile: medullary thyroid carcinoma and severe GI disease. It is on the WADA Prohibited List for athletes. This is reference information, not medical advice.
How does Cagrilintide work?
Cagrilintide is a long-acting analog of human amylin, the beta-cell hormone co-secreted with insulin. Substitutions that reduce the aggregation seen with native human amylin, together with fatty-acid acylation that promotes albumin binding, extend its half-life enough for weekly dosing.
Is Cagrilintide FDA approved?
No. Cagrilintide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What is the half-life of Cagrilintide?
Reported half-life for Cagrilintide is ~6–7 days. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Cagrilintide?
Cagrilintide has the sequence Modified amylin peptide, engineered for long-acting stability, giving a chain of 2 amino acids. Its molecular formula is Not publicly available.
Is Cagrilintide banned in sport?
Cagrilintide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
How long does Cagrilintide take to show effects in research protocols?
The research protocol on this profile lists an expected onset of 1-2 weeks appetite, 4-8 weeks weight loss. This is a protocol note describing when studies and researchers report observing changes, not a measured clinical outcome, and it varies with the model, dose and endpoint studied.
Where is Cagrilintide administered in research protocols?
Research protocols on this profile use subcutaneous administration, with recorded sites including abdomen, thigh. Site rotation and sterile technique are standard practice in the research literature; this describes protocol conditions and is not guidance for use.
References
- Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials — Endocrinol Diabetes Metab, 2026External reference
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — N Engl J Med, 2025External reference
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes — N Engl J Med, 2025External reference
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial — Lancet, 2023External reference
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial — Lancet, 2021External reference
Related research, comparisons & guides
- CagriSema: Two Molecules in One Injection
- Semaglutide
- GLP-1 and metabolic peptidesCategory
- Peptide stacks: combinations by research goalStacks
- Peptide dosage chart: dose, route and frequencyCategory
- Cagrilintide calculator: reconstitution and syringe units
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 26, 2026 · Version 5
This Cagrilintide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Cagrilintide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →